A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas: the ARROVEN study

Biotechnology Computer Science Energy Engineering Environmental Sciences Information Science Life Sciences Mathematics Medical Sciences

Military Sciences Natural Sciences Physical Sciences Plant Sciences Science Space Sciences Technology Transportation